{
  "findings": [
    {
      "id": "Q01",
      "metric": "Fraction of tumor proteins in immunopeptidome",
      "value": "62.3%",
      "comparator_or_baseline": "37.3%",
      "interpretation": "Intratumoral mRNA vaccination resulted in a substantially broader representation of tumor proteins in the MHC-bound peptide pool, indicating enhanced antigen display capability",
      "evidence_line_refs": ["L28"]
    },
    {
      "id": "Q02",
      "metric": "Fraction of proteins in MHC-I peptidome",
      "value": "40.6%",
      "comparator_or_baseline": "20.6%",
      "interpretation": "The MHC-I presented peptide landscape nearly doubled following vaccination, demonstrating a strong expansion of the antigen presentation repertoire",
      "evidence_line_refs": ["L29"]
    },
    {
      "id": "Q03",
      "metric": "Retrospective human survival comparison p-value",
      "value": "p=0.01",
      "comparator_or_baseline": "N/A",
      "interpretation": "The vaccinated subgroup demonstrated statistically significant improved survival outcomes compared to unvaccinated patients when receiving ICI treatment",
      "evidence_line_refs": ["L30"]
    },
    {
      "id": "Q04",
      "metric": "Type I interferon response score",
      "value": "3.1 normalized units",
      "comparator_or_baseline": "1.0 normalized units",
      "interpretation": "mRNA vaccination induced a marked 3.1-fold increase in type I interferon signaling within the tumor microenvironment",
      "evidence_line_refs": ["L31"]
    },
    {
      "id": "Q05",
      "metric": "PD-L1 expression fold-change",
      "value": "2.4x",
      "comparator_or_baseline": "1.0x",
      "interpretation": "PD-L1 expression in tumor tissue increased 2.4-fold following vaccination, making the checkpoint axis more therapeutically targetable",
      "evidence_line_refs": ["L32"]
    },
    {
      "id": "Q06",
      "metric": "Intratumoral CD8+ T-cell density fold-change",
      "value": "1.8x",
      "comparator_or_baseline": "1.0x",
      "interpretation": "Combination therapy with vaccine and ICI resulted in increased CD8+ T-cell infiltration into tumor tissue",
      "evidence_line_refs": ["L33"]
    }
  ],
  "controls_or_null_results": [
    {
      "statement": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models, demonstrating the necessity of combining with ICI for therapeutic effect",
      "evidence_line_ref": "L36"
    },
    {
      "statement": "ICI-only treatment showed limited activity in low-immunogenic baseline tumor settings, highlighting the importance of vaccine-induced priming",
      "evidence_line_ref": "L37"
    },
    {
      "statement": "Lipid particle controls lacking mRNA did not reproduce the sensitization effect, confirming that the mRNA component is essential for the observed phenomenon",
      "evidence_line_ref": "L38"
    },
    {
      "statement": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit, demonstrating that interferon signaling is mechanistically required for vaccine-mediated tumor sensitization",
      "evidence_line_ref": "L39"
    }
  ]
}